FTC Alleges Drug Makers Monopolized Market for Opioid Drug
- January 29, 2021
The Federal Trade Commission (FTC) has sued Endo Pharmaceuticals Inc., Endo International plc, Impax Laboratories, LLC, and Impax’s owner, Amneal Pharmaceuticals, Inc., for alleged antitrust violations. According to the FTC, an agreement between Endo and Impax eliminated competition in the market for oxymorphone ER, a long-acting opioid used to treat moderate to severe pain.
ARTICLE TAGS
You must be logged in to access this content.